Diffuse (anergic) cutaneous leishmaniasis responding to amphotericin B: Clinical dermatology • Concise report

Clinical and Experimental Dermatology

Volumn 35, Issue 4, 2010, Pages

  Morrison, B ^a   Mendoza, I ^b   Delgado, D ^b   Reyes Jaimes, O ^c   Aranzazu, N ^d   Paniz Mondolfi, A E ^c,e,f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Dermatology Health Service   (Venezuela)

^c Department of Dermatopathology   (United States)

^d INSTITUTO DE BIOMEDICINA   (Venezuela)

^e Venezuelan Institute of Social Insurance   (Venezuela)

^f BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BCG VACCINE; LEISHMANIA VACCINE; MEGLUMINE ANTIMONATE; MILTEFOSINE;

ACANTHOSIS; ADOLESCENT; AMASTIGOTE; ARTICLE; CASE REPORT; DISEASE EXACERBATION; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HYPERKERATOSIS; LEISHMANIA MEXICANA; LEISHMANIN SKIN TEST; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROMASTIGOTE; REMISSION; SKIN CULTURE; SKIN LEISHMANIASIS; VENEZUELA;

ADOLESCENT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; FACIAL DERMATOSES; HUMANS; LEISHMANIASIS, DIFFUSE CUTANEOUS; MALE;

EID: 77951221737     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03737.x     Document Type: Article

References (10)

1. Magill AJ. Leishmaniasis. In : Hunter's Tropical Medicine and Emerging Infectious Diseases, 8th edn (Strickland GT, Magill AJ, Laughlin LW, eds).
2. Blum J, Desjeux P, Schwartz E et al. Treatment of cutaneous leishmaniasis among travelers. J Antimicrob Chemother 2004 53 : 158 166.
3. Convit J, Kerdel-Vegas F. Disseminated cutaneous leishmaniasis. Arch Dermatol 1965 91 : 439 447.
4. Silveira FT, Lainson R, Corbett CEP. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil - a review. Mem Inst Oswaldo Cruz 2004 99 : 239 251. (Pubitemid 38822274)
5. Machado-Pinto J, Azulay RD. Leishmaniasis. In : Tropical Dermatology, 1st edn (Tyring SK, Lupi O, Hengge UR, eds).
6. Convit J, Ulrich M, Fernandez CT et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1993 87 : 444 448. (Pubitemid 23262710)
7. Singh S, Sivakumar R. Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 2004 10 : 307 315. (Pubitemid 40142819)
8. Calvopina M, Gomez EA, Sindermann H et al. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am J Trop Med Hyg 2006 75 : 1074 1077. (Pubitemid 351627483)
9. Amato VS, Tuon FF, Campos A et al. Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B. Clin Infect Dis 2007 44 : 311 312. (Pubitemid 46080001)
10. Paradisi A, Capizzi R, Zampetti A et al. Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B. J Infect 2005 51 : 261 264. (Pubitemid 43008973)